A webcast of the presentation will be accessible through the Investors section of the Company's website, www.immunogen.com. Following the live webcast, a replay will be available at the same location for approximately two weeks.
ImmunoGen is a clinical-stage biotechnology company that develops
targeted cancer therapeutics using its proprietary ADC technology.
ImmunoGen's lead product candidate, mirvetuximab soravtansine, is in a
Phase 3 trial for FRα-positive platinum-resistant ovarian cancer, and is
in Phase 1b/2 testing in combination regimens for earlier-stage disease.
ImmunoGen's ADC technology is used in Roche's marketed product, Kadcyla®,
in other clinical-stage ImmunoGen product candidates, and in programs in
development by Amgen, Bayer, Biotest, CytomX,
Kadcyla® is a registered trademark of
This press release includes forward-looking statements. For these statements, ImmunoGen claims the protection of the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. It should be noted that there are risks and uncertainties related to the development of novel anticancer products, including mirvetuximab soravtansine, including risks related to preclinical and clinical studies, their timings and results. A review of these risks can be found in ImmunoGen's Annual Report on Form 10-K for the fiscal year ended December 31, 2016 and other reports filed with the Securities and Exchange Commission.
Courtney O'Konek, 781-895-0600
FTI Consulting Inc.
Robert Stanislaro, 212-850-5657
News Provided by Acquire Media